nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—DHFR—Methotrexate—testicular cancer	0.848	1	CbGbCtD
Trimetrexate—DHFR—embryo—testicular cancer	0.00476	0.249	CbGeAlD
Trimetrexate—Hepatotoxicity—Chlorambucil—testicular cancer	0.00456	0.0343	CcSEcCtD
Trimetrexate—DHFR—seminal vesicle—testicular cancer	0.00447	0.234	CbGeAlD
Trimetrexate—Serum creatinine increased—Ifosfamide—testicular cancer	0.00379	0.0285	CcSEcCtD
Trimetrexate—Hepatotoxicity—Dactinomycin—testicular cancer	0.00329	0.0247	CcSEcCtD
Trimetrexate—Serum creatinine increased—Cisplatin—testicular cancer	0.00327	0.0245	CcSEcCtD
Trimetrexate—DHFR—gonad—testicular cancer	0.00323	0.169	CbGeAlD
Trimetrexate—Hepatotoxicity—Ifosfamide—testicular cancer	0.00302	0.0227	CcSEcCtD
Trimetrexate—Hypocalcaemia—Dactinomycin—testicular cancer	0.00278	0.0209	CcSEcCtD
Trimetrexate—DHFR—female gonad—testicular cancer	0.00262	0.137	CbGeAlD
Trimetrexate—Hepatotoxicity—Cisplatin—testicular cancer	0.0026	0.0195	CcSEcCtD
Trimetrexate—Hypocalcaemia—Ifosfamide—testicular cancer	0.00255	0.0191	CcSEcCtD
Trimetrexate—Hepatotoxicity—Etoposide—testicular cancer	0.00238	0.0179	CcSEcCtD
Trimetrexate—DHFR—testis—testicular cancer	0.00233	0.122	CbGeAlD
Trimetrexate—Neutropenia—Chlorambucil—testicular cancer	0.00207	0.0155	CcSEcCtD
Trimetrexate—Body temperature increased—Carboplatin—testicular cancer	0.00193	0.0145	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Etoposide—testicular cancer	0.00184	0.0138	CcSEcCtD
Trimetrexate—DHFR—lymph node—testicular cancer	0.00169	0.0884	CbGeAlD
Trimetrexate—Serum creatinine increased—Epirubicin—testicular cancer	0.00168	0.0126	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Dactinomycin—testicular cancer	0.00166	0.0125	CcSEcCtD
Trimetrexate—Blood creatinine increased—Ifosfamide—testicular cancer	0.00159	0.0119	CcSEcCtD
Trimetrexate—Serum creatinine increased—Doxorubicin—testicular cancer	0.00155	0.0117	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Etoposide—testicular cancer	0.00154	0.0115	CcSEcCtD
Trimetrexate—Neutropenia—Dactinomycin—testicular cancer	0.00149	0.0112	CcSEcCtD
Trimetrexate—Hyponatraemia—Cisplatin—testicular cancer	0.00146	0.011	CcSEcCtD
Trimetrexate—Hepatotoxicity—Methotrexate—testicular cancer	0.00143	0.0107	CcSEcCtD
Trimetrexate—Anaemia—Chlorambucil—testicular cancer	0.00142	0.0107	CcSEcCtD
Trimetrexate—Blood creatinine increased—Cisplatin—testicular cancer	0.00137	0.0103	CcSEcCtD
Trimetrexate—Convulsion—Chlorambucil—testicular cancer	0.00133	0.01	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.00131	0.00987	CcSEcCtD
Trimetrexate—Anaemia—Vinblastine—testicular cancer	0.0013	0.0098	CcSEcCtD
Trimetrexate—Confusional state—Chlorambucil—testicular cancer	0.00127	0.00952	CcSEcCtD
Trimetrexate—Thrombocytopenia—Chlorambucil—testicular cancer	0.00123	0.00925	CcSEcCtD
Trimetrexate—Convulsion—Vinblastine—testicular cancer	0.00122	0.00919	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00118	0.00885	CcSEcCtD
Trimetrexate—Thrombocytopenia—Vinblastine—testicular cancer	0.00113	0.00847	CcSEcCtD
Trimetrexate—Hypocalcaemia—Epirubicin—testicular cancer	0.00113	0.00847	CcSEcCtD
Trimetrexate—Anaemia—Bleomycin—testicular cancer	0.0011	0.00828	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Epirubicin—testicular cancer	0.00109	0.0082	CcSEcCtD
Trimetrexate—Fatigue—Chlorambucil—testicular cancer	0.00108	0.00814	CcSEcCtD
Trimetrexate—Neutropenia—Etoposide—testicular cancer	0.00108	0.00811	CcSEcCtD
Trimetrexate—Hypocalcaemia—Doxorubicin—testicular cancer	0.00104	0.00784	CcSEcCtD
Trimetrexate—Feeling abnormal—Chlorambucil—testicular cancer	0.00104	0.00778	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Epirubicin—testicular cancer	0.00103	0.00775	CcSEcCtD
Trimetrexate—Anaemia—Dactinomycin—testicular cancer	0.00103	0.00772	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Doxorubicin—testicular cancer	0.00101	0.00758	CcSEcCtD
Trimetrexate—Body temperature increased—Chlorambucil—testicular cancer	0.000994	0.00747	CcSEcCtD
Trimetrexate—Confusional state—Bleomycin—testicular cancer	0.000981	0.00737	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Doxorubicin—testicular cancer	0.000955	0.00717	CcSEcCtD
Trimetrexate—Thrombocytopenia—Bleomycin—testicular cancer	0.000953	0.00716	CcSEcCtD
Trimetrexate—Feeling abnormal—Vinblastine—testicular cancer	0.000949	0.00713	CcSEcCtD
Trimetrexate—Anaemia—Ifosfamide—testicular cancer	0.000942	0.00707	CcSEcCtD
Trimetrexate—Asthenia—Chlorambucil—testicular cancer	0.000902	0.00678	CcSEcCtD
Trimetrexate—Pruritus—Chlorambucil—testicular cancer	0.000889	0.00668	CcSEcCtD
Trimetrexate—Thrombocytopenia—Dactinomycin—testicular cancer	0.000888	0.00667	CcSEcCtD
Trimetrexate—Convulsion—Ifosfamide—testicular cancer	0.000883	0.00663	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Epirubicin—testicular cancer	0.000861	0.00647	CcSEcCtD
Trimetrexate—Confusional state—Ifosfamide—testicular cancer	0.000838	0.0063	CcSEcCtD
Trimetrexate—Asthenia—Vinblastine—testicular cancer	0.000827	0.00621	CcSEcCtD
Trimetrexate—Thrombocytopenia—Ifosfamide—testicular cancer	0.000814	0.00612	CcSEcCtD
Trimetrexate—Anaemia—Cisplatin—testicular cancer	0.000812	0.0061	CcSEcCtD
Trimetrexate—Feeling abnormal—Bleomycin—testicular cancer	0.000802	0.00602	CcSEcCtD
Trimetrexate—Vomiting—Chlorambucil—testicular cancer	0.000799	0.00601	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Doxorubicin—testicular cancer	0.000797	0.00599	CcSEcCtD
Trimetrexate—Fatigue—Dactinomycin—testicular cancer	0.000782	0.00588	CcSEcCtD
Trimetrexate—Body temperature increased—Bleomycin—testicular cancer	0.000769	0.00578	CcSEcCtD
Trimetrexate—Convulsion—Cisplatin—testicular cancer	0.000761	0.00572	CcSEcCtD
Trimetrexate—Hyponatraemia—Epirubicin—testicular cancer	0.000752	0.00565	CcSEcCtD
Trimetrexate—Feeling abnormal—Dactinomycin—testicular cancer	0.000748	0.00562	CcSEcCtD
Trimetrexate—Nausea—Chlorambucil—testicular cancer	0.000747	0.00561	CcSEcCtD
Trimetrexate—Anaemia—Etoposide—testicular cancer	0.000744	0.00559	CcSEcCtD
Trimetrexate—Vomiting—Vinblastine—testicular cancer	0.000732	0.0055	CcSEcCtD
Trimetrexate—Body temperature increased—Dactinomycin—testicular cancer	0.000717	0.00539	CcSEcCtD
Trimetrexate—Fatigue—Ifosfamide—testicular cancer	0.000717	0.00539	CcSEcCtD
Trimetrexate—Thrombocytopenia—Cisplatin—testicular cancer	0.000702	0.00527	CcSEcCtD
Trimetrexate—Blood creatinine increased—Epirubicin—testicular cancer	0.000702	0.00527	CcSEcCtD
Trimetrexate—Asthenia—Bleomycin—testicular cancer	0.000698	0.00524	CcSEcCtD
Trimetrexate—Convulsion—Etoposide—testicular cancer	0.000697	0.00524	CcSEcCtD
Trimetrexate—Hyponatraemia—Doxorubicin—testicular cancer	0.000696	0.00523	CcSEcCtD
Trimetrexate—Pruritus—Bleomycin—testicular cancer	0.000688	0.00517	CcSEcCtD
Trimetrexate—Feeling abnormal—Ifosfamide—testicular cancer	0.000685	0.00515	CcSEcCtD
Trimetrexate—Nausea—Vinblastine—testicular cancer	0.000684	0.00514	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000675	0.00507	CcSEcCtD
Trimetrexate—Confusional state—Etoposide—testicular cancer	0.000662	0.00498	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000661	0.00496	CcSEcCtD
Trimetrexate—Body temperature increased—Ifosfamide—testicular cancer	0.000657	0.00494	CcSEcCtD
Trimetrexate—Asthenia—Dactinomycin—testicular cancer	0.000651	0.00489	CcSEcCtD
Trimetrexate—Blood creatinine increased—Doxorubicin—testicular cancer	0.000649	0.00488	CcSEcCtD
Trimetrexate—Neutropenia—Methotrexate—testicular cancer	0.000647	0.00486	CcSEcCtD
Trimetrexate—Thrombocytopenia—Etoposide—testicular cancer	0.000643	0.00483	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000624	0.00469	CcSEcCtD
Trimetrexate—Vomiting—Bleomycin—testicular cancer	0.000619	0.00465	CcSEcCtD
Trimetrexate—Rash—Bleomycin—testicular cancer	0.000613	0.00461	CcSEcCtD
Trimetrexate—Dermatitis—Bleomycin—testicular cancer	0.000613	0.0046	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000611	0.00459	CcSEcCtD
Trimetrexate—Neutropenia—Epirubicin—testicular cancer	0.000605	0.00455	CcSEcCtD
Trimetrexate—Asthenia—Ifosfamide—testicular cancer	0.000597	0.00448	CcSEcCtD
Trimetrexate—Feeling abnormal—Cisplatin—testicular cancer	0.000591	0.00444	CcSEcCtD
Trimetrexate—Pruritus—Ifosfamide—testicular cancer	0.000588	0.00442	CcSEcCtD
Trimetrexate—Nausea—Bleomycin—testicular cancer	0.000578	0.00434	CcSEcCtD
Trimetrexate—Vomiting—Dactinomycin—testicular cancer	0.000577	0.00433	CcSEcCtD
Trimetrexate—Rash—Dactinomycin—testicular cancer	0.000572	0.0043	CcSEcCtD
Trimetrexate—Body temperature increased—Cisplatin—testicular cancer	0.000567	0.00426	CcSEcCtD
Trimetrexate—Fatigue—Etoposide—testicular cancer	0.000566	0.00425	CcSEcCtD
Trimetrexate—Neutropenia—Doxorubicin—testicular cancer	0.00056	0.00421	CcSEcCtD
Trimetrexate—Feeling abnormal—Etoposide—testicular cancer	0.000541	0.00407	CcSEcCtD
Trimetrexate—Nausea—Dactinomycin—testicular cancer	0.000539	0.00405	CcSEcCtD
Trimetrexate—Vomiting—Ifosfamide—testicular cancer	0.000529	0.00397	CcSEcCtD
Trimetrexate—Rash—Ifosfamide—testicular cancer	0.000524	0.00394	CcSEcCtD
Trimetrexate—Dermatitis—Ifosfamide—testicular cancer	0.000524	0.00394	CcSEcCtD
Trimetrexate—Body temperature increased—Etoposide—testicular cancer	0.000519	0.0039	CcSEcCtD
Trimetrexate—Asthenia—Cisplatin—testicular cancer	0.000514	0.00386	CcSEcCtD
Trimetrexate—Nausea—Ifosfamide—testicular cancer	0.000494	0.00371	CcSEcCtD
Trimetrexate—Asthenia—Etoposide—testicular cancer	0.000471	0.00354	CcSEcCtD
Trimetrexate—Pruritus—Etoposide—testicular cancer	0.000465	0.00349	CcSEcCtD
Trimetrexate—Vomiting—Cisplatin—testicular cancer	0.000456	0.00342	CcSEcCtD
Trimetrexate—Rash—Cisplatin—testicular cancer	0.000452	0.0034	CcSEcCtD
Trimetrexate—Dermatitis—Cisplatin—testicular cancer	0.000452	0.00339	CcSEcCtD
Trimetrexate—Anaemia—Methotrexate—testicular cancer	0.000446	0.00335	CcSEcCtD
Trimetrexate—Nausea—Cisplatin—testicular cancer	0.000426	0.0032	CcSEcCtD
Trimetrexate—Convulsion—Methotrexate—testicular cancer	0.000418	0.00314	CcSEcCtD
Trimetrexate—Vomiting—Etoposide—testicular cancer	0.000418	0.00314	CcSEcCtD
Trimetrexate—Anaemia—Epirubicin—testicular cancer	0.000417	0.00313	CcSEcCtD
Trimetrexate—Rash—Etoposide—testicular cancer	0.000414	0.00311	CcSEcCtD
Trimetrexate—Dermatitis—Etoposide—testicular cancer	0.000414	0.00311	CcSEcCtD
Trimetrexate—Confusional state—Methotrexate—testicular cancer	0.000397	0.00298	CcSEcCtD
Trimetrexate—Convulsion—Epirubicin—testicular cancer	0.000391	0.00294	CcSEcCtD
Trimetrexate—Nausea—Etoposide—testicular cancer	0.00039	0.00293	CcSEcCtD
Trimetrexate—Anaemia—Doxorubicin—testicular cancer	0.000386	0.0029	CcSEcCtD
Trimetrexate—Thrombocytopenia—Methotrexate—testicular cancer	0.000385	0.00289	CcSEcCtD
Trimetrexate—Confusional state—Epirubicin—testicular cancer	0.000371	0.00279	CcSEcCtD
Trimetrexate—Convulsion—Doxorubicin—testicular cancer	0.000362	0.00272	CcSEcCtD
Trimetrexate—Thrombocytopenia—Epirubicin—testicular cancer	0.00036	0.00271	CcSEcCtD
Trimetrexate—Confusional state—Doxorubicin—testicular cancer	0.000343	0.00258	CcSEcCtD
Trimetrexate—Fatigue—Methotrexate—testicular cancer	0.000339	0.00255	CcSEcCtD
Trimetrexate—Thrombocytopenia—Doxorubicin—testicular cancer	0.000334	0.00251	CcSEcCtD
Trimetrexate—Feeling abnormal—Methotrexate—testicular cancer	0.000324	0.00244	CcSEcCtD
Trimetrexate—Fatigue—Epirubicin—testicular cancer	0.000317	0.00238	CcSEcCtD
Trimetrexate—Body temperature increased—Methotrexate—testicular cancer	0.000311	0.00234	CcSEcCtD
Trimetrexate—Feeling abnormal—Epirubicin—testicular cancer	0.000303	0.00228	CcSEcCtD
Trimetrexate—Fatigue—Doxorubicin—testicular cancer	0.000294	0.00221	CcSEcCtD
Trimetrexate—Body temperature increased—Epirubicin—testicular cancer	0.000291	0.00219	CcSEcCtD
Trimetrexate—Asthenia—Methotrexate—testicular cancer	0.000282	0.00212	CcSEcCtD
Trimetrexate—Feeling abnormal—Doxorubicin—testicular cancer	0.000281	0.00211	CcSEcCtD
Trimetrexate—Pruritus—Methotrexate—testicular cancer	0.000278	0.00209	CcSEcCtD
Trimetrexate—Body temperature increased—Doxorubicin—testicular cancer	0.000269	0.00202	CcSEcCtD
Trimetrexate—Asthenia—Epirubicin—testicular cancer	0.000264	0.00198	CcSEcCtD
Trimetrexate—Pruritus—Epirubicin—testicular cancer	0.00026	0.00196	CcSEcCtD
Trimetrexate—Vomiting—Methotrexate—testicular cancer	0.00025	0.00188	CcSEcCtD
Trimetrexate—Rash—Methotrexate—testicular cancer	0.000248	0.00186	CcSEcCtD
Trimetrexate—Dermatitis—Methotrexate—testicular cancer	0.000248	0.00186	CcSEcCtD
Trimetrexate—Asthenia—Doxorubicin—testicular cancer	0.000244	0.00184	CcSEcCtD
Trimetrexate—Pruritus—Doxorubicin—testicular cancer	0.000241	0.00181	CcSEcCtD
Trimetrexate—Vomiting—Epirubicin—testicular cancer	0.000234	0.00176	CcSEcCtD
Trimetrexate—Nausea—Methotrexate—testicular cancer	0.000234	0.00176	CcSEcCtD
Trimetrexate—Rash—Epirubicin—testicular cancer	0.000232	0.00174	CcSEcCtD
Trimetrexate—Dermatitis—Epirubicin—testicular cancer	0.000232	0.00174	CcSEcCtD
Trimetrexate—Nausea—Epirubicin—testicular cancer	0.000219	0.00164	CcSEcCtD
Trimetrexate—Vomiting—Doxorubicin—testicular cancer	0.000217	0.00163	CcSEcCtD
Trimetrexate—Rash—Doxorubicin—testicular cancer	0.000215	0.00161	CcSEcCtD
Trimetrexate—Dermatitis—Doxorubicin—testicular cancer	0.000215	0.00161	CcSEcCtD
Trimetrexate—Nausea—Doxorubicin—testicular cancer	0.000202	0.00152	CcSEcCtD
